Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Schizophrenia Research. Cognition|March 11, 2020
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety studyGahan Pandina, Isaac Nuamah, Timothy Petersen, et al.
International Clinical Psychopharmacology|August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 18, 2019
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studiesAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Current Medical Research and Opinion|April 21, 2010
Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse preventionDeborah Nicholl, Henry Nasrallah, Isaac Nuamah, et al.
Innovations in Clinical Neuroscience|September 17, 2011
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophreniaSrihari Gopal, Gahan Pandina, Rosanne Lane, et al.
Patient Preference and Adherence|August 6, 2020
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference QuestionnaireClifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Neuropsychiatric Disease and Treatment|June 1, 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed doseMahesh N Samtani, Isaac Nuamah, Srihari Gopal, et al.
Clinical Drug Investigation|June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup AnalysisMaju Mathews, Huiling Pei, Adam Savitz, et al.
NPJ Schizophrenia|July 29, 2017
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studiesSrihari Gopal, Haiyan Xu, Kelly McQuarrie, et al.
Schizophrenia Research|October 23, 2013
Effect of parental age on treatment response in adolescents with schizophreniaMark Opler, Dolores Malaspina, Srihari Gopal, et al.
Pageof 5